Skip to main content
Erschienen in: Familial Cancer 4/2014

01.12.2014 | Original Article

Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP

verfasst von: Rachel A. Levy, Vanessa W. Hui, Rupa Sood, Stephanie Fish, Arnold J. Markowitz, Richard J. Wong, José G. Guillem

Erschienen in: Familial Cancer | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Cribriform-morular variant (CMV) is a rare subtype of papillary thyroid carcinoma (PTC) that is associated with familial adenomatous polyposis (FAP). Given the high likelihood for multi-organ malignancies in FAP patients, this study explores the yield of diagnosing occult FAP among CMV-PTC patients. Institutional database was searched in order to identify patients with pathologically-confirmed CMV-PTC from 2000 to 2012. Medical records were reviewed, and clinical and pathological features were analyzed. Eleven cases of CMV were identified from 6,901 patients with PTC, for a prevalence of 0.16 %. All 11 patients were female. The median age at CMV-PTC diagnosis was 36 years (range 18–46). Two patients had pre-existing FAP at the time of PTC diagnosis. The other nine patients were referred for colonoscopy and/or genetic testing. Six patients underwent colonoscopy and one (17 %) was diagnosed with FAP based on polyposis phenotype and genetic testing. The mean age of patients at the time of CMV-PTC diagnosis was younger in the FAP group (23 years, range 18–34) than in the sporadic group (37 years, range 25–46). All three patients with FAP-associated CMV-PTC had multicentric tumors, while all five sporadic patients did not. Our study found that approximately one-sixth of patients with CMV-PTC may have occult FAP. Patients with FAP-associated CMV-PTC appear to be younger and more likely to have multicentric tumors than those with sporadic CMV-PTC. Due to the increased risk of malignancy in patients with FAP, patients with CMV-PTC should be referred for colonoscopy and/or genetic evaluation for FAP.
Literatur
2.
Zurück zum Zitat Harach HR, Williams GT, Williams ED (1994) Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25(6):549–561PubMedCrossRef Harach HR, Williams GT, Williams ED (1994) Familial adenomatous polyposis associated thyroid carcinoma: a distinct type of follicular cell neoplasm. Histopathology 25(6):549–561PubMedCrossRef
4.
Zurück zum Zitat Perrier ND, van Heerden JA, Goellner JR, Williams ED, Gharib H, Marchesa P, Church JM, Fazio VW, Larson DR (1998) Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 22(7):738–742 discussion 743PubMedCrossRef Perrier ND, van Heerden JA, Goellner JR, Williams ED, Gharib H, Marchesa P, Church JM, Fazio VW, Larson DR (1998) Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 22(7):738–742 discussion 743PubMedCrossRef
5.
Zurück zum Zitat Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV, Kelley NC, Hamilton SR (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34(10):1394–1396PubMedCentralPubMedCrossRef Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV, Kelley NC, Hamilton SR (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 34(10):1394–1396PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Bulow S, Holm NV, Mellemgaard A (1988) Papillary thyroid carcinoma in Danish patients with familial adenomatous polyposis. Int J Colorectal Dis 3(1):29–31PubMedCrossRef Bulow S, Holm NV, Mellemgaard A (1988) Papillary thyroid carcinoma in Danish patients with familial adenomatous polyposis. Int J Colorectal Dis 3(1):29–31PubMedCrossRef
7.
Zurück zum Zitat Bulow C, Bulow S (1997) Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle polyposis group. Int J Colorectal Dis 12(4):240–242PubMedCrossRef Bulow C, Bulow S (1997) Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle polyposis group. Int J Colorectal Dis 12(4):240–242PubMedCrossRef
8.
Zurück zum Zitat van der Linde K, Vasen HF, van Vliet AC (1998) Occurrence of thyroid carcinoma in Dutch patients with familial adenomatous polyposis. An epidemiological study and report of new cases. Eur J Gastroenterol Hepatol 10(9):777–781PubMedCrossRef van der Linde K, Vasen HF, van Vliet AC (1998) Occurrence of thyroid carcinoma in Dutch patients with familial adenomatous polyposis. An epidemiological study and report of new cases. Eur J Gastroenterol Hepatol 10(9):777–781PubMedCrossRef
9.
Zurück zum Zitat Plail RO, Bussey HJ, Glazer G, Thomson JP (1987) Adenomatous polyposis: an association with carcinoma of the thyroid. Br J Surg 74(5):377–380PubMedCrossRef Plail RO, Bussey HJ, Glazer G, Thomson JP (1987) Adenomatous polyposis: an association with carcinoma of the thyroid. Br J Surg 74(5):377–380PubMedCrossRef
10.
Zurück zum Zitat Herraiz M, Barbesino G, Faquin W, Chan-Smutko G, Patel D, Shannon KM, Daniels GH, Chung DC (2007) Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5(3):367–373. doi:10.1016/j.cgh.2006.10.019 PubMedCrossRef Herraiz M, Barbesino G, Faquin W, Chan-Smutko G, Patel D, Shannon KM, Daniels GH, Chung DC (2007) Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 5(3):367–373. doi:10.​1016/​j.​cgh.​2006.​10.​019 PubMedCrossRef
11.
Zurück zum Zitat Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, Stadler ZK, Markowitz AJ (2012) The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer 11(4):304–308. doi:10.1016/j.clcc.2012.01.006 PubMedCrossRef Steinhagen E, Guillem JG, Chang G, Salo-Mullen EE, Shia J, Fish S, Stadler ZK, Markowitz AJ (2012) The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer 11(4):304–308. doi:10.​1016/​j.​clcc.​2012.​01.​006 PubMedCrossRef
12.
13.
Zurück zum Zitat Steinhagen E, Hui VW, Levy RA, Markowitz AJ, Fish S, Wong RJ, Sood R, Ochman SM, Guillem JG (In press) Results of a prospective thyroid utrasound screening program in adenomatous polyposis patients. Am J Surg Steinhagen E, Hui VW, Levy RA, Markowitz AJ, Fish S, Wong RJ, Sood R, Ochman SM, Guillem JG (In press) Results of a prospective thyroid utrasound screening program in adenomatous polyposis patients. Am J Surg
14.
Zurück zum Zitat Crail HW (1949) Multiple primary malignancies arising in the rectum, brain, and thyroid; report of a case. US Nav Med Bull 49(1):123–128 Crail HW (1949) Multiple primary malignancies arising in the rectum, brain, and thyroid; report of a case. US Nav Med Bull 49(1):123–128
15.
Zurück zum Zitat Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Kuma S, Kuma K, Kakudo K (2004) Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28(9):886–889PubMedCrossRef Tomoda C, Miyauchi A, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Kuma S, Kuma K, Kakudo K (2004) Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 28(9):886–889PubMedCrossRef
16.
Zurück zum Zitat Kurihara K, Shimizu S, Chong J, Hishima T, Funata N, Kashiwagi H, Nagai H, Miyaki M, Fukayama M (2000) Nuclear localization of immunoreactive beta-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma. Jpn J Cancer Res 91(11):1100–1102PubMedCrossRef Kurihara K, Shimizu S, Chong J, Hishima T, Funata N, Kashiwagi H, Nagai H, Miyaki M, Fukayama M (2000) Nuclear localization of immunoreactive beta-catenin is specific to familial adenomatous polyposis in papillary thyroid carcinoma. Jpn J Cancer Res 91(11):1100–1102PubMedCrossRef
17.
Zurück zum Zitat Boonyaarunnate T, Olson MT, Bishop JA, Yang GC, Ali SZ (2013) Cribriform morular variant of papillary thyroid carcinoma: clinical and cytomorphological features on fine-needle aspiration. Acta Cytol 57(2):127–133. doi:10.1159/000345879 PubMedCrossRef Boonyaarunnate T, Olson MT, Bishop JA, Yang GC, Ali SZ (2013) Cribriform morular variant of papillary thyroid carcinoma: clinical and cytomorphological features on fine-needle aspiration. Acta Cytol 57(2):127–133. doi:10.​1159/​000345879 PubMedCrossRef
18.
Zurück zum Zitat Cameselle-Teijeiro J, Chan JK (1999) Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol 12(4):400–411PubMed Cameselle-Teijeiro J, Chan JK (1999) Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol 12(4):400–411PubMed
19.
Zurück zum Zitat Chikkamuniyappa S, Jagirdar J (2004) Cribriform-morular variant of papillary carcinoma: association with familial adenomatous polyposis—report of three cases and review of literature. Int J Med Sci 1(1):43–49PubMedCentralPubMedCrossRef Chikkamuniyappa S, Jagirdar J (2004) Cribriform-morular variant of papillary carcinoma: association with familial adenomatous polyposis—report of three cases and review of literature. Int J Med Sci 1(1):43–49PubMedCentralPubMedCrossRef
20.
21.
Zurück zum Zitat Ito Y, Miyauchi A, Ishikawa H, Hirokawa M, Kudo T, Tomoda C, Miya A (2011) Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J 58(8):685–689PubMedCrossRef Ito Y, Miyauchi A, Ishikawa H, Hirokawa M, Kudo T, Tomoda C, Miya A (2011) Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J 58(8):685–689PubMedCrossRef
22.
Zurück zum Zitat Ng SB, Sittampalam K, Goh YH, Eu KW (2003) Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation. Pathology 35(1):42–46PubMed Ng SB, Sittampalam K, Goh YH, Eu KW (2003) Cribriform-morular variant of papillary carcinoma: the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma. A case report with clinical and molecular genetic correlation. Pathology 35(1):42–46PubMed
23.
Zurück zum Zitat Xu B, Yoshimoto K, Miyauchi A, Kuma S, Mizusawa N, Hirokawa M, Sano T (2003) Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol 199(1):58–67. doi:10.1002/path.1225 PubMedCrossRef Xu B, Yoshimoto K, Miyauchi A, Kuma S, Mizusawa N, Hirokawa M, Sano T (2003) Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol 199(1):58–67. doi:10.​1002/​path.​1225 PubMedCrossRef
24.
Zurück zum Zitat Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet Part A 152A(2):327–332. doi:10.1002/ajmg.a.33139 PubMedCrossRef Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet Part A 152A(2):327–332. doi:10.​1002/​ajmg.​a.​33139 PubMedCrossRef
27.
Zurück zum Zitat Sinha A, Tekkis PP, Rashid S, Phillips RK, Clark SK (2010) Risk factors for secondary proctectomy in patients with familial adenomatous polyposis. Br J Surg 97(11):1710–1715. doi:10.1002/bjs.7202 PubMedCrossRef Sinha A, Tekkis PP, Rashid S, Phillips RK, Clark SK (2010) Risk factors for secondary proctectomy in patients with familial adenomatous polyposis. Br J Surg 97(11):1710–1715. doi:10.​1002/​bjs.​7202 PubMedCrossRef
Metadaten
Titel
Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP
verfasst von
Rachel A. Levy
Vanessa W. Hui
Rupa Sood
Stephanie Fish
Arnold J. Markowitz
Richard J. Wong
José G. Guillem
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2014
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9732-5

Weitere Artikel der Ausgabe 4/2014

Familial Cancer 4/2014 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.